Tag: Addyi interactions
-
FDA Expands Addyi Approval to Treat Postmenopausal Libido – What It Means and What to Know
Low sexual desire after menopause is common, and on December 15, 2025 the FDA expanded the label for Addyi (flibanserin) to include some postmenopausal women. This is a notable change: Addyi was first approved in 2015 for certain premenopausal women, and the new decision gives doctors another FDA‑cleared option for women under 65 who meet